Greathouse Currently available once-daily, fixed-dose combinations, such as olmesartan medoxomil/HCTZ and other ARB/HCTZ combinations, may simplify treatment regimens. Olmesartan medoxomil/HCTZ is effective and allows lower doses of component agents to be used compared with monotherapy, minimizing the likelihood of adverse events associated with higher doses of HCTZ (Neutel 2001; Chrysant et al 2004). These features may enhance patients’ acceptance of therapy and potentially increase the likelihood that they will continue with therapy through each successive stage of the treatment algorithm. In summary, olmesartan medoxomil/HCTZ is an effective and well-tolerated combination antihypertensive therapy. It provides greater antihypertensive efficacy than either component given as monotherapy, and may provide a useful treatment option in patients unable to achieve BP goal with monotherapy. Acknowledgments Support for the preparation of this manuscript was provided by Daiichi Sankyo, Inc. We would like to express our thanks to Alan J Klopp, PhD, for his editorial assistance in the preparation of this manuscript. References American Heart Association and A. S. Association. 2006. Heart disease and stroke statistics - 2006 update [online]. Accessed 3 March 2006. URL: http://www.americanheart.org Ball KJ, Williams PA, Stumpe KO. 2001. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens, 19(Suppl 1):S49-56. Benz JR, Black HR, Graff A, et al. 1998. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens, 12:861-6. Brown CL, Backhouse CI, Grippat JC, et al. 1990. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol, 39:327-32. Brunner HR, Nussberger J. 2001. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens, 19(Suppl 1):S15-20. Burnier M. 2001. Angiotensin II type 1 receptor blockers. Circulation, 103:904-12. Caro JJ, Speckman JL, Salas M, et al. 1999. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ, 160:41-6. Carter BL, Ernst ME, Cohen JD. 2004. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension, 43:4-9. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52. Chrysant SG. 1994. Antihypertensive effectiveness of low-dose lisinopril- hydrochlorothiazide combination. A large multicenter study. Arch Intern Med, 154:737-43. Chrysant SG, Weber MA, Wang AC, et al. 2004. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens, 17:252-59. Conlin PR, Spence JD, Williams B, et al. 2000. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens, 13:418-26. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003. Daiichi Sankyo, Inc. 2005. Benicar HCT Prescribing Information. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertens, 21:1011-53. Izzo JL, Levy D Jr., Black HR. 2000. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 35:1021-4. Kjeldsen SE, Os I, Hoieggen A, et al. 2005. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs, 5:17-22. Kochar M, Guthrie R, Triscari J, et al. 1999. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens, 12:797-805. Koike H, Sada T, Triscari J, et al. 2001. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens, 19(Suppl):S3-14. Kreutz R, Bolbrinker J, Huber T. 2006. Pharmacokinetics of olmesartan plus hydrochlorothiazide combination in healthy subjects. Clin Drug Invest, 26:29-34. Lacourciere Y, Neutel JM, Schumacher H. 2005. Comparison of fixed- dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/ hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther, 27:1795-805. Laeis P, Puchler K, Kirch W. 2001. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens, 19(Suppl):S21-32. Mancia G, Bombelli M, Lanzarotti A, et al. 2002. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med, 162:582-6. Manolis A J, Grossman E, Jelakovic B, et al. 2000. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther, 22:1186-203. McGill JB, Reilly PA. 2001. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther, 23:833-50. Meredith PA. 2005. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs, 5:171-83. Mizuno M, Sada T, Ikeda M, et al. 1995. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol, 285:181-8. Neutel JM. 2001. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol, 87(Suppl):37C-43C. 408 Vascular Health and Risk Management 2006:2(4)